



Advancing science for life

2025 IMPACT REPORT
HIGHLIGHTS





Contents

Patient spotlights	3
CEO message	5
Company overview	6
2025 corporate responsibility highlights	7
Corporate responsibility framework	8
Materiality index	9





Advancing science for life: expanding access through medical innovation

Boston Scientific develops minimally invasive technologies designed to tackle some of healthcare’s most complex challenges. Innovation drives everything we do and guides the development of solutions that address unmet patient needs and improve health outcomes for patients and communities globally.

Advancing science for life means working to ensure that innovation reaches patients in ways that reduce treatment burden, expand clinical options and improve quality of life. These stories represent a portion of the patients served by our [core businesses](#).

> [Visit our website](#) for more stories about how our solutions have helped patients across clinical areas



Condition: Atrial fibrillation (AF)
Patient: Mariano (Costa Rica)
Treatment: FARAPULSE™ Pulsed Field Ablation Platform

Electrical engineer Mariano lived with atrial fibrillation that caused shortness of breath, heart palpitations and fatigue, in addition to frequent worry of stroke. After cryoablation and a pacemaker failed to resolve his arrhythmia, he underwent pulsed field ablation (PFA) using FARAPULSE PFA, which includes the FARAWAVE™ PFA Catheter. Mariano has been arrhythmia-free since the procedure and back to the routine of his daily life.

Our approach
FARAPULSE PFA uses non-thermal electric fields to precisely target and treat heart tissue while minimizing damage to surrounding structures. This tissue-selective approach reflects the evolution of AF treatment toward more predictable, safe and reproducible ablation. FARAWAVE, the platform’s catheter, is designed to effectively ablate a wide range of unique patient anatomies.

> [Watch](#) Mariano’s story



Condition: Obesity
Patient: Yves (United Kingdom (U.K.))
Treatment: Endoscopic Sleeve Gastroplasty using OverStitch™

Following cancer treatment and prolonged isolation during COVID-19, Yves gained significant weight and struggled physically and emotionally. He underwent endoscopic sleeve gastroplasty, a minimally invasive, same-day procedure that reduced his stomach volume without surgery. He describes the procedure as a turning point that helped him restart his health journey.

Our approach
More than 25% of U.K. adults live with obesity, yet most clinically eligible patients do not pursue bariatric surgery. Many people want options that are somewhere between medication and undergoing surgery. Endoscopic sleeve gastroplasty — an incisionless, organ-sparing intervention — is designed to fill that gap. For patients that might otherwise go untreated, this option can broaden access to an evidence-based weight-loss treatment.

> [Read more](#) about Yves’ story



Condition: Incontinence
Patient: Karen (United States (U.S.))
Treatment: Axonics™ Sacral Neuromodulation Therapy

Karen’s bladder and bowel control challenges dictated her daily routines and limited her ability to stay active. After receiving sacral neuromodulation therapy, she regained symptom control, started running again and resumed her active life. Treatment restored her independence and confidence.

Our approach
Millions of people live with urinary and bowel dysfunction, often delaying care because of its stigma or because they have cycled through treatments that have not provided lasting relief. Sacral neuromodulation offers a long-term, minimally invasive option for patients whose symptoms persist. It expands access to durable symptom control and offers the potential to improve quality of life.

> [Watch](#) Karen’s story



Advancing science for life: Expanding access through medical innovation continued



Condition: Cancer
Patients: Nicole, Esther and James (U.S.)

Nicole — TheraSphere™ Y-90 Glass Microspheres
When Nicole was diagnosed with hepatocellular carcinoma, the tumor in her liver was too large for surgery. Physicians used TheraSphere Y-90 to deliver high doses of radiation directly to the tumor, which reduced the tumor size so it could be surgically removed. She has been cancer-free for nearly a decade.

Esther — Visual ICE™ Cryoblation System
Esther, who lives with metastatic breast cancer, sought relief from painful bone tumors. A single cryoablation procedure reduced her pain and let her quickly return to daily activity, which included completing a marathon.

James — SpaceOAR™ Hydrogel
During prostate cancer radiation, James chose an absorbable hydrogel designed to reduce radiation exposure to healthy tissue. He completed treatment without significant side effects.

Our approach
Cancer care increasingly prioritizes survival and quality of life. Our oncology solutions include a spectrum of minimally invasive approaches that target tumors, destroy cancerous tissue and protect healthy anatomy during radiation. Together, these innovations expand treatment pathways and help reduce treatment burden and side effects.

> [Read more](#) about Nicole, Esther and James' story

STRATEGIC ACQUISITIONS TO REDEFINE PATIENT CARE



Nalu Medical, Inc.



SoniVie Ltd.



Bolt Medical, Inc.

To expand our capacity to transform lives, we invest in and acquire emerging technologies, early-stage companies and commercial businesses. Our venture portfolio and acquisition strategy prioritize novel therapies and technologies in high-growth, adjacent markets.

Our investments are focused on innovations that improve our ability to address complex conditions and reinforce our category leadership strategy.

Advancing targeted pain therapy
The acquisition of **Nalu Medical, Inc.** expands our capabilities in peripheral nerve stimulation for chronic pain. Its miniaturized, battery-free system delivers targeted therapy at the source of patients' pain. Today, our broad portfolio of therapies give physicians more flexibility to tailor treatments to individual needs. And together, the therapies enable us to deliver less invasive pain relief options to physicians to help treat a wider variety of patients.

Innovating in hypertension treatment
Our agreement to acquire **SoniVie Ltd.** strengthens our pipeline in hypertension care, a major risk factor for cardiovascular disease. The investigational TIVUS™ Intravascular Ultrasound System is a minimally invasive approach designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders. This emerging therapy has the potential to help millions of people around the world manage high blood pressure more effectively.

Enhancing treatment of calcified arterial disease
With the acquisition of **Bolt Medical, Inc.**, we have added an innovative intravascular lithotripsy platform to our portfolio. Through a minimally invasive approach, its laser-based technology addresses a significant unmet need for patients with complex calcified arterial disease. Intravascular lithotripsy is one of the fastest growing medical device segments, and this technology provides a platform for future innovation.



A message from our chairman and chief executive officer

Boston Scientific is guided by a spirit of relentless innovation and a deep commitment to our purpose of advancing science for life. In 2025, that spirit translated into actions that helped improve the lives of more than 48 million patients¹ around the world. Behind that number are millions of individual stories of people who are now able to spend more time with loved ones and live life more fully. We are privileged to play a role in these journeys, and we do not take that responsibility lightly.

To meet growing patient needs, we invested approximately \$2 billion, or 10% of our annual sales revenue, in research and development, and we continued to generate strong clinical evidence to support safe, effective and less invasive care. We expanded our global manufacturing and supply chain capabilities, embedding digital technologies and automation to enhance quality, resilience and operational efficiency. We also provided training and education to healthcare providers, which broadens access to our therapies and supports high-quality patient care.

At the heart of this progress is our team of 59,000 highly engaged global employees who live our core values and help create a vibrant and strong culture. Their dedication

extends beyond their daily work. In 2025, they supported hundreds of community initiatives worldwide through volunteerism and giving. We also advanced our environmental goals, reinforcing our belief that human and planetary health are inseparable. We are making steady progress toward our science-based target of achieving net-zero greenhouse gas emissions by 2050. Since 2024, our key manufacturing and distribution sites have been powered by 100% renewable electricity.

Unmet needs in healthcare remain significant. I am confident that our talented global team will continue to meet these challenges with focus and determination. Together, we will continue advancing science for life and delivering meaningful innovation for patients, customers and communities worldwide.

Mike Mahoney
chairman and chief executive officer
Boston Scientific

“Boston Scientific is guided by a spirit of relentless innovation and a deep commitment to advancing science for life. We are privileged to play a role in patients’ journeys, and we do not take that responsibility lightly.”



¹ Our estimate of the patients we serve each year is based on annual company revenue, product pricing, and product and procedure volume.




Company overview

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare.

> Visit our [Investor Relations website](#) to learn more about our category leadership strategy and growth opportunities

2025 net sales (dollars in millions)

By region



NET SALES

\$20,074



U.S. \$12,864

Europe, Middle East and Africa (EMEA) \$3,451

Asia-Pacific (APAC) \$3,080

Latin America and Canada (LACA) \$678

By business



Awards and recognition



FORTUNE (2016-2026)
World's Most Admired

JUST CAPITAL AND CNBC (2020-2022, 2024-2025)
America's Most JUST Companies

DOW JONES (2020-2024)
Sustainability Index North America

GLASSDOOR (2018-2019, 2022, 2024 AND 2026)
Employees' Choice Best Place to Work

> Visit our [website](#) for a full list of awards

Amounts may not add up due to rounding.



2025 corporate responsibility highlights



Innovative care

Developing meaningful innovation to help people live longer, better lives.
> [Learn more](#) about Innovative care.

78

25,777

10.2%

active clinical trials¹

patients enrolled in clinical trials globally¹

R&D spend as a percent of sales²



Empowered people

Providing opportunities to empower people and strengthen communities.
> [Learn more](#) about Empowered people.

91%

99%+

\$162M

employees proud to work at Boston Scientific

pay equity³

contributed to medical research, fellowships, education and charitable organizations globally



Healthier planet

Building sustainable solutions to reduce our impact on the environment.
> [Learn more](#) about Healthier planet.

100%

75%

47%

renewable electricity at key manufacturing and distribution sites⁴

solid, non-hazardous waste recycled⁵

reduction in scope 1 and 2 emissions since 2019



Performance with integrity

Our commitment to ethical business practices is anchored by strong governance and compliance, risk management, cybersecurity and responsible supply chains.
> [Learn more](#) about Performance with integrity

96%

99%

100%

corrective and preventive actions (CAPA) deemed effective⁶

employees who completed code of conduct training⁷

comprehensive assessment of critical (Tier 1) suppliers annually

1. Active clinical trial is defined as a clinical trial that existed during the reporting year with an active subject enrolled. An active subject is defined as someone who is enrolled in a clinical trial who has not died, withdrawn or completed the study. Studies are included even if the active subject withdrew, died, or the study was closed during the reporting period. Active studies do not include retrospective studies, surveys, investigator sponsored research (ISRs), real world evidence (RWE) and collaboratives.

2. Represents GAAP R&D expense as a percentage of GAAP net sales per Annual Report on Form 10-K.

3. In 2025, Boston Scientific began working with an external consultant and technology platform to enable multiple regression statistical pay equity analyses, this process included refinement of our methodology. The Pay Equity analyses for 2025 were conducted over homogenous job families and subfamilies in our global career framework spanning our global workforce in 2025 based on pay as of September 2025, with the exception of our United States sales workforce which we anticipate future capabilities to analyze. Boston Scientific defines 'pay equity' as similar pay for similar work.

4. Includes renewable electricity generated onsite (e.g., solar) and purchased electricity matched with electricity attributed to renewable sources via energy attribute certificates (EACs) purchased through the open market, purchased through an energy provider, or associated with virtual Power Purchase Agreements.

5. Inclusive of key manufacturing and distribution sites only.

6. Percentage of self-identified CAPAs initiated and evaluated in the reporting year deemed effective meaning the solutions adequately addressed the CAPA problem statements and met the predefined 'effective' criteria.

7. Excludes direct labor.



Our corporate responsibility framework

We embed transparency, accountability and continuous improvement into how we manage and report our performance. As industry expectations and best practices evolve, we update our disclosures and strengthen our processes to ensure our reporting remains accurate and consistent.

Our strategy for responsible growth

We align our strategy with patient needs while integrating environmental and social considerations into our operations. Responsible growth is embedded throughout our culture, shaping how we innovate, collaborate and drive progress.

We engage with stakeholders across our global ecosystem and work with organizations aligned to advancing healthcare and addressing environmental and social priorities.

Our focus is organized around three pillars, all grounded by a commitment to business integrity:

- Innovative care
- Empowered people
- Healthier planet

Our approach to strong governance

As a leading medical technology business, we focus on enhancing health outcomes for patients through rigorous research, scientific discipline, strong governance and collaboration across our organization.

These principles guide how we govern and manage corporate responsibility. Subject matter experts and key advisors establish performance metrics and reporting standards. This includes an internal committee — comprising leaders from legal, regulatory, investor relations, finance and corporate communications — to support consistent and controlled disclosures. Our vice president of Corporate Responsibility leads our global strategy, ensures progress and accountability, and regularly updates the Executive Committee and Board of Directors, including its Nominating and Governance Committee.

Reinforcing performance

Corporate responsibility performance is integrated into our annual employee bonus program through a companywide modifier tied to progress against defined goals. This incentive program links performance outcomes to compensation and supports long-term value creation.

> [Visit our 2026 Proxy Statement](#) for more information



Materiality index



Boston Scientific recognizes that understanding the environmental, social and governance (ESG) topics most important to our stakeholders and business is essential to managing risk and maximizing positive impact. In 2024, we partnered with an independent third party to conduct an updated ESG materiality assessment. The process included stakeholder interviews, peer benchmarking and alignment with leading sustainability frameworks. We engaged internal subject matter experts and external stakeholders to validate and prioritize key topics, with results reviewed by our senior management.

Through this assessment, we identified 12 priority material topics with the greatest potential impact on our business and stakeholders. These priorities guide our corporate responsibility strategy, align with our core values and inform ongoing governance, prioritization and refinement of our approach. We regularly review and refine our approach to remain aligned with evolving expectations and track our progress.

> [Visit our 2025 Data Pack](#) to learn more about our progress across key areas

ENVIRONMENT

[Healthier planet](#)

[Climate change](#)

We are working to reduce greenhouse gas emissions across our operations and value chain while strengthening resilience to climate-related risks.

[Relevant sources](#)

- [Environment, Health & Safety Policy](#)
- [Global Energy Management System Policy](#)
- [Climate-related Financial Disclosure](#)
- [CDP Climate Change](#)

SOCIAL

[Innovative care](#)

[Product innovation for patient needs](#)

Driving breakthrough therapies through science, strategic investments, partnerships and digital advancement.

[Relevant sources](#)

[Product quality and patient health and safety](#)

Quality and safety are embedded from product design through post-market performance, supported by rigorous systems and continuous oversight.

[Relevant sources](#)

- [How we approach quality](#)

[Access and equity](#)

We are dedicated to reducing health disparities and expanding access to care worldwide, regardless of socioeconomic status, geography or background.

[Relevant sources](#)

- [Close the gap webpage](#)



Materiality index continued

SOCIAL

 [Empowered people](#)

Human capital attraction and development

When our employees grow in careers that matter, build future-ready skills and use new technologies to work more effectively, we advance our mission together.

Relevant sources

[Careers webpage](#)

Employee engagement, well-being and work-related rights

We foster an environment where employees feel heard, supported and respected.

Relevant sources

[Our benefits](#)
[Human rights policy](#)
[Labor and human rights page](#)

Inclusive workforce

We are committed to building a high-performing workforce with a broad range of perspectives and experiences, helping us better serve patients, customers and communities.

Relevant sources

[Employee resource groups \(ERGs\)](#)

Employee health and safety

We maintain a safe and healthy workplace through proactive risk management, global standards and continuous improvement.

Relevant sources

[Environment, Health & Safety Policy](#)

GOVERNANCE

 [Performance with integrity](#)

Business ethics and compliance

We embed ethical business practices across our global operations to operate with transparency, trust and compliance.

Relevant sources

[Code of Conduct](#)
[Compliance and ethics](#)

Corporate governance and oversight

Our Board provides independent oversight to uphold accountability, integrity and long-term value creation.

Relevant sources

[Governance overview](#)
[Corporate governance guidelines](#)

Data security, cybersecurity and privacy

We work to protect our products, systems and personal data through resilient cybersecurity, privacy governance and secure-by-design product development.

Relevant sources

[Product security](#)
[Privacy policy](#)

Supply chain management

We operate a resilient, responsible supply chain which includes ethical sourcing, supplier oversight and proactive risk management.

Relevant sources

[Supplier code of conduct](#)
[How we approach a resilient supply chain](#)
[Human Rights Policy](#)
[Global modern slavery statement](#)
[Labor and human rights page](#)

